Section Arrow
Quote
MDGL.NASDAQ
- Madrigal Pharmaceuticals
Quotes are at least 15-min delayed:2026/04/14 19:25 EDT
After Hours
Last
 529.6879
+4.6979 (+0.89%)
Bid
500.01
Ask
530.3
High 530.41211 
Low 524.99 
Volume 6.35K 
Regular Hours (Closed)
Last
 524.99
-0.68 (-0.13%)
Day High 
539.165 
Prev. Close
525.67 
1-M High
572.195 
Volume 
302.74K 
Bid
500.01
Ask
530.3
Day Low
518.8 
Open
532.1 
1-M Low
427.76 
Market Cap 
12.06B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 524.06 
20-SMA 492.31 
50-SMA 470.09 
52-W High 615 
52-W Low 265 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-12.85/8.73
Enterprise Value
12.41B
Balance Sheet
Book Value Per Share
26.27
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
958.40M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
HOTHHoth Therapeutics0.6459+0.134+26.18%-- 
After Hours 0.65 +0.0041 +0.63%
ALLOAllogene Therapeutics2.28-0.78-25.49%-- 
After Hours 2.19 -0.09 -3.95%
VRAXVirax Biolabs Group Limited0.148-0.0184-11.06%-- 
After Hours 0.1384 -0.0096 -6.49%
CMNDClearmind Medicine Inc.0.91-0.52-36.36%-- 
After Hours 0.8558 -0.0542 -5.96%
REPLReplimune Group1.95+0.25+14.71%-- 
After Hours 1.9001 -0.0499 -2.56%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.